Chinese manufacturer of large-volume intravenous infusion solutions and generic injectable drugs for hospitals.
Chinese manufacturer of large-volume intravenous infusion solutions and generic injectable drugs for hospitals.
Sells IV solutions and injectables in bulk to hospitals, largely through distributors, with prices set in government-run provincial bidding rounds, so winning tenders matters more than branding.
In one line: A Chinese Baxter International-style IV-fluids and generic-injectables maker.
Moat: narrow (scale, regulatory licence, distribution). Large manufacturing scale and hospital distribution network for commodity IV products.
Headquarters: Guangzhou, China · Founded: 1988 · Employees: 5,500
Size SSY (2005.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $948M, the 595th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$2.52 on 18 Nov 2026.
Performance Over six months the shares gained 7.7%, against -20.3% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 4th highest of 21 in its peer set.
Growth Revenue fell 4.4% over the last twelve months (peer median +2.4%); the operating margin is 12.2% (peer median 8.8%).
Valuation It trades at 12.5× forward earnings against a peer median of 24.5× (2nd cheapest of 10).
Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is +3 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.0 points below its cost of capital (6.2% WACC).
Next results Next results expected around 26 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$4.38B | HK$4.17B | HK$5.77B | HK$6.46B | HK$6.43B |
| Revenue growth | — | -28% | -11% | 0% | — |
| Gross profit | HK$1.70B | HK$1.62B | HK$2.81B | HK$3.49B | HK$3.44B |
| EBITDA | HK$985M | HK$886M | HK$1.68B | HK$1.93B | HK$1.73B |
| Net income | HK$507M | HK$471M | HK$1.06B | HK$1.32B | HK$1.12B |
| Free cash flow | HK$898M | HK$559M | HK$221M | HK$437M | HK$584M |
| Capital expenditure | HK$228M | HK$241M | HK$540M | HK$704M | HK$418M |
| Total debt | n/a | HK$4.01B | HK$3.64B | HK$3.37B | HK$3.21B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| SSY 2005.HK | $948M | +8% | -4% | 12% | 12.5× | 2.3% |
| Sichuan Kelun Pharmaceutical 002422.SZ | $10.1B | +35% | 0% | 9% | 35.6× | 6.2% |
| Livzon Pharmaceutical 1513.HK | $3.73B | -9% | -10% | 19% | 11.3× | -7.0% |
| Baxter International BAX | $13.5B | +39% | +5% | 6% | 12.7× | 13.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2005.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.2% | -9.1% | 8th highest of 21 |
| 6-month return | +7.7% | -20.3% | 4th highest of 21 |
| Distance from 52-week high | -20.8% | -46.9% | 3rd highest of 21 |
| Revenue growth (TTM) | -4.4% | +2.4% | 9th lowest of 18 |
| Operating margin | 12.2% | 8.8% | 9th highest of 18 |
| Forward P/E | 12.5× | 24.5× | 2nd cheapest of 10 |
| Growth the price implies (Req g, 7 yrs) | 2.3% | 8.4% | 3rd least demanding of 11 |
| Growth delivered (Del g) | -0.5% | +8.5% | 4th lowest of 11 |
| Hurdle (Req g minus delivered) | +2.8 pp | +1.5 pp | 6th least demanding of 11 |
| ROIC minus cost of capital | -2.0 pp | -2.0 pp | 8th highest of 16 |
| EV / EBITDA | 10.0× | 15.9× | 2nd cheapest of 7 |
| Net debt / EBITDA | 2.1× | 1.8× | 3rd most indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| SSY 2005.HK | Hong Kong | $948M | +8% | -4% | 12% | 12.5× | 2.3% | -0.5% |
| Strides Pharma Science STAR.NS | India | $946M | -17% | +11% | 14% | 15.9× | 17.6% | +7.8% |
| Ningbo Menovo Pharmaceutical 603538.SS | China | $945M | -48% | +19% | 9% | 42.3× | 11.6% | +4.9% |
| Harbin Gloria Pharmaceuticals 002437.SZ | China | $941M | -9% | -16% | 13% | n/a | 7.7% | -6.9% |
| KPC Pharmaceuticals 600422.SS | China | $940M | -6% | -41% | -10% | n/a | n/a | n/a |
| China Resources Boya Bio-pharmaceutical 300294.SZ | China | $959M | -21% | -27% | -19% | 21.4× | n/a | n/a |
| BeBetter Med 688759.SS | China | $960M | -58% | n/a | n/a | n/a | n/a | n/a |
| Guangxi Wuzhou Zhongheng 600252.SS | China | $936M | -10% | -43% | -42% | n/a | 10.3% | -13.7% |
| Bio-Thera Solutions 688177.SS | China | $929M | -23% | +24% | -44% | n/a | n/a | n/a |
| Oscotec 039200.KS | South Korea | $923M | -32% | +510% | 59% | 50.2× | -10.2% | +18.1% |
| Nxera Pharma 4565.T | Japan | $974M | +46% | +24% | 14% | 25.8× | 17.7% | +27.3% |
| Zhejiang Garden Biopharmaceutical 300401.SZ | China | $922M | -14% | +2% | 24% | 22.9× | 9.1% | +13.4% |
| Lotus Pharmaceutical 1795.TW | Taiwan | $921M | -37% | +67% | 21% | 9.8× | -3.7% | +13.8% |
| MoonLake Immunotherapeutics MLTX | United States | $918M | -37% | n/a | n/a | n/a | n/a | n/a |
| Procter & Gamble Health PGHL.NS | India | $979M | +3% | +13% | 31% | 24.5× | 5.6% | +9.3% |
| Seaport Therapeutics SPTX | United States | $980M | +16% | n/a | n/a | n/a | n/a | n/a |
| Chongqing Taiji Industry (Group) 600129.SS | China | $982M | -20% | -4% | 2% | 69.8× | n/a | n/a |
| InventisBio 688382.SS | China | $982M | -47% | -61% | -563% | n/a | 6.5% | -60.6% |
| Aarti Pharmalabs AARTIPHARM.NS | India | $984M | +44% | +13% | 18% | n/a | n/a | n/a |
| Immatics IMTX | United States | $913M | -46% | -44% | -589% | n/a | n/a | n/a |
| Genfleet Therapeutics (Shanghai) 2595.HK | Hong Kong | $912M | -42% | -55% | -457% | n/a | n/a | n/a |